Journal of International Psychiatry

Abstract: Objective: To investigate the effect of aripiprazole in combination with olanzapine on glucolipid metabolism and myocardial enzyme of patients with elderly schizophrenia and to analyze the possible mechanism of combined treatment. Methods: A total of 60 cases of patients with elderly schizophrenia were randomly divided into Observation Group and Control Group, with 30 cases in each group. Patients in Control Group were treated by olanzapine, and those in Observation Group were treated by aripiprazole in combination with olanzapine. After 12 weeks of treatment, glucolipid metabolism, myocardial enzymes, clinical efficacy, adverse reactions and other indicators of the two groups were compared. Results: The effective rate of Observation Group was 93.33% and significantly higher than 73.33% of Control Group (P<0.05); the levels of GLU, total cholesterol(TC), triglyceride(TG) and low density lipoprotein(LDL) were significantly lower than in Control Group; the level of high-density lipoprotein(HDL) was significantly higher than in Control Group(P< 0.05); serum aspartate amino transferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK) and creatine kinase-MB (CK-MB) were significantly lower than in Control Group(P<0.05, P<0.01); the incidence rate of salivation and other adverse reactions was 13.33% and significantly lower than 36.67% of Control Group (P<0.05). Conclusion: Aripiprazole in combination with olanzapine is conductive to improving the clinical efficacy of patients with elderly schizophrenia and reducing adverse reactions, besides, the therapy exerts little effect on glucolipid metabolism and myocardial enzyme.

Keywords: elderly schizophrenia; olanzapine; aripiprazole; glucolipid metabolism; myocardial enzyme